Pralatrexate is a folate antagonist and dihydrofolate reductase inhibitor used in the treatment of peripheral T-cell lymphoma, where it functions by inhibiting DNA synthesis in cancer cells. This category… Read more



























Pralatrexate is a folate antagonist and dihydrofolate reductase inhibitor used in the treatment of peripheral T-cell lymphoma, where it functions by inhibiting DNA synthesis in cancer cells. This category provides essential pharmaceutical reference standards, including the active pharmaceutical ingredient (API), related stereoisomers, and synthetic impurities necessary for rigorous impurity profiling and method validation. Laboratories utilize these high-quality compounds, alongside stable isotope labelled versions of pralatrexate, to ensure accurate quantification and identification during analytical testing and quality control procedures. By incorporating these materials into development and stability studies, researchers can effectively monitor the purity and degradation profile of the drug. These analytical tools are vital for maintaining compliance with regulatory standards and ensuring the consistency of pharmaceutical products throughout the manufacturing and testing lifecycle.